The underlisted safety variations have been submitted by Marketing Authorization Holders (MAHs) and approved by the Food and Drugs Authority in line with the Variation Guidelines for Allopathic Medicines.These safety variations are being shared with healthcare professionals and patients.

| Safety Updates | | | | | | |
|---|---|---|---|---|---|---|
| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
| 1 | Actified Cold Syrup | Triprolidine hydrochloride and Pseudoephedrine hydrochloride | Warnings and Precautions | Revision of text to read "There have been reports of acute systemic vasoconstrictive events with pseudoephedrine. Significant examples include: Acute Coronary Syndrome (ACS): Symptoms include sudden chest pain, tightness, heavy sweating and dyspnoea at rest. Ischaemic colitis: Symptoms include sudden abdominal pain and rectal bleeding. Posterior reversible encephalopathy (PRES)/reversible cerebral vasoconstriction syndrome (RCVS): Symptoms included sudden onset of severe headache, nausea, vomiting, and visual disturbances. Most cases improved or resolved within a few days following appropriate treatment. Pseudoephedrine should be discontinued immediately, and medical advice sought if any signs/symptoms of vasoconstrictive events develop." | 17/7/2023 | GSK Export Limited |
| | | | | | | |
| 2 | Dalacin C | Clindamycin Palmitate Hydrochloride | Warnings | Revision of text to read “Clindamycin is potentially nephrotoxic and cases with acute kidney injury have been reported. Consider monitoring of renal function particularly in patients with pre-existing renal dysfunction or those taking concomitant nephrotoxic drugs. In case of acute kidney injury, discontinue DALACIN C when no other etiology is identified.” Under the sub-heading Nephrotoxicity. | 9/6/2023 | Pfizer |
| | | | | | | |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 3 | Enbrel | Etanercept | Fertility, Pregnancy and Lactation | Revision of text to read "The effects of etanercept on pregnancy outcomes have been investigated in two observational cohort studies. One pregnancy registry compared rates of major birth defects in liveborn infants of mothers with rheumatic diseases or psoriasis exposed to Enbrel in the first trimester (n = 319) versus those unexposed to Enbrel during pregnancy (n = 144). The all-inclusive adjusted odds ratio for major birth defects was 2.77 (95% CI 1.04-7.35) and when chromosomal and known genetic disorders were removed was 2.49 (95% CI 0.92-6.68). The findings showed no increased rate of minor malformations, and no pattern of major or minor malformations. In addition, there was no increase in rates of intrauterine or postnatal growth deficits or delayed postnatal development. In a second observational multi-country registry study comparing the risk of adverse pregnancy outcomes in women exposed to etanercept (n = 522) to those exposed to non-biologic drugs (n = 3508), there was no observed increased risk of major birth defects (adjusted odds ratio 0.96, 95% CI: 0.58-1.60). This study also showed no increased risks of minor birth defects, preterm birth, stillbirth or infections in the first year of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used during pregnancy if the potential benefits to the mother outweigh the potential risks to the fetus. Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility and general reproductive performance are not available. | 9/6/2023 | Pfizer |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 3 | Enbrel | Etanercept | Fertility, Pregnancy and Lactation | The AUC-based systemic exposures of etanercept in rats and rabbits are 21- to 25-times higher than in humans at the usual human therapeutic dose of 50 mg weekly, and are approximately 10- to 13-times higher than in humans at the maximum recommended human dose of etanercept of 50 mg twice weekly (for psoriasis). No evidence of harm to the fetus in rats or rabbits or neonatal rats due to etanercept was observed. Animal reproduction studies are not always predictive of human response. Etanercept crosses the placenta and has been detected in the serum of infants born to female patients treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be at increased risk of infection. dministration of live vaccines to infants for 16 weeks after the mother's last dose of Enbrel is generally not recommended. In lactating rats, following subcutaneous dministration etanercept was excreted in the milk and detected in the serum of the pups. Limited information from the published literature indicates etanercept has been detected at low levels in human milk. Etanercept could be considered for use during breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. | 9/6/2023 | Pfizer |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 3 | Enbrel | Etanercept | Fertility, Pregnancy and Lactation | While systemic exposure in a breastfed infant is expected to be low because etanercept is largely degraded in the gastrointenstinal tract, limited data regarding systemic exposure in the breastfed infant are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an earlier time point if the infant etanercept serum levels are undetectable)" | 9/6/2023 | Pfizer |
| | | | | | | |
| 4 | Jardiance | Empagliflozin | Indications | Addition of sub-section "Heart failure"<br><br>Addition of text to read "JARDIANCE® is indicated in adult patients with heart failure (NYHA class II-IV) and reduced ejection fraction, with or without type 2 diabetes mellitus: □ to reduce the risk of cardiovascular death and hospitalization for heart failure to slow kidney function decline." under sub-section Heart failure | 21/8/2023 | Boehringer Ingelheim |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 4 | Jardiance | Empagliflozin | Dosage and Administration | Addition of sub-section "Heart failure"<br><br>Addition of text to read "The recommended dose of JARDIANCE® is 10 mg once daily." Under sub-section Heart failure<br><br>Addition of text to read " Glycaemic control, Prevention of cardiovascular events in patients with type 2 diabetes mellitus and high cardiovascular risk" Under sub-section Patients with renal impairment (Type 2 diabetes mellitus)<br><br>Addition of text to read "Treatment of patients with heart failure and reduced ejection fraction, with or without type 2 diabetes mellitus. JARDIANCE® is not recommended for use in patients with eGFR <20 ml/min/1.73 m2 (see Special warnings and precautions). There are insufficient data to support use in these patients " Under sub-section Patients with renal impairment (Heart failure).<br><br>Revision of text to read "Treatment of patients with heart failure with or without type 2 diabetes mellitus " Under sub-section Patients with renal impairment (Heart failure). | 21/8/2023 | Boehringer Ingelheim |
| | | | Adverse Reactions | Addition of sub section "Gastrointestinal disorders"<br>Addition of text to read "Constipation" Under sub-section gastrointestinal disorders. | | |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 4 | Jardiance | Empagliflozin | Indications/ Usage | Revision of text to read "JARDIANCE® is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus: to reduce the risk of cardiovascular death and hospitalization for heart failure; to slow kidney function decline" under sub-section heart failure | 21/8/2023 | Boehringer Ingelheim |
| | | | | | | |
| 5 | Medrol | Methylprednisolone | Undesirable effects | Addition of text "Flushing" under sub-section Vascular Disorders | 13/11/2023 | Pfizer |
| | | | | | | |
| 6 | Suyana PRESS | Medroxyprogesterone Acetate | How to use SUYANA PRESS | Revision of text to read "Your usual level of fertility will return when the effect of the last injection has worn off. The time this takes varies in different women, and does not depend on how long you have been using SAYANA PRESS. In most women the effect will have worn off within one year after the last injection." Under sub-section What if you decide to get pregnant? | 13/11/2023 | Pfizer |
| | | | Possible side effects | Addition of text "Injection site discolouration" Under sub-section rare. | | |
| | | | | | | |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 7 | Tazocin | Piperacillin/ Tazobactam | Undesirable effects | Addition of text to read "Kounis syndrome" Under sub-section Adverse Drug Reaction. | 1/11/2023 | Pfizer |
| | | | | | | |
| 8 | Taxotere | Docetaxel | Clinical Particulars | Addition of text to read "Women of childbearing potential must use contraceptive measures during treatment and for 2 months after cessation of treatment with docetaxel. Men must use contraceptive measures during treatment and for 4 months after cessation of treatment with docetaxel" under sub-section Special warnings and precautions for use<br><br>Addition of sub-topic "Women of childbearing potential/Contaception in males and females" under sub section Fertility, pregnancy and lactation<br><br>Addition of text "Women of childbearing potential and men receiving docetaxel should be advised to avoid becoming pregnant, and not to father a child and to inform the treating physician immediately should this occur. Due to the genotoxic risk of docetaxel (see section 5.3), women of childbearing potential must use effective method of contraception during treatment and for 2 months after cessation of treatment with docetaxel. Men must use effective method of contraception during treatment and for 4 months after cessation of treatment with docetaxel." Under sub-section Fertility, pregnancy and lactation (under Sub-topic Women of childbearing potential/Contaception in males and females ). | 13/12/2023 | Sanofi Aventis Limited |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 9 | Taxotere | Docetaxel | Clinical Particulars | Revision of text to read "There is no information on the use of docetaxel in pregnant women. Docetaxel has been shown to be both embryotoxic and foetotoxic in rabbits and rats. As with other cytotoxic medicinal products, docetaxel may cause foetal harm when administered to pregnant women. Therefore, docetaxel must not be used during pregnancy unless clearly indicated" under sub-section Fertility, pregnancy and lactation(under Sub-topic Pregnancy )<br><br>Deletion of text "An effective method of contraception should be used during treatment." under sub-section Fertility, pregnancy and lactation(under Sub-topic Contraception in males and females)<br><br>Deletion of sub-topic "Contraception in males and females" under sub-section Fertility, pregnancy and lactation<br><br>Revision of text to read "Studies in animals have shown that docetaxel may alter male fertility (see section 5.3). Therefore,males being treated with docetaxel must seek advice on conservation of sperm prior to treatment." under sub-section Fertility, pregnancy and lactation (under Sub-topic Fertility). | 13/12/2023 | Sanofi Aventis Limited |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 9 | Taxotere | Docetaxel | What you need to know before you use TAXOTERE | Revision of text to read "Ask your doctor for advice before being given any medicine.<br><br>TAXOTERE must NOT be administered if you are pregnant unless clearly indicated by your doctor.<br><br>You must not become pregnant during treatment and for 2 months after end of treatment with this medicine,.You must use an effective method of contraception during treatment and for 2 months after end of treatment, TAXOTERE may be harmful for the unborn baby. If pregnancy occurs during your treatment, you must immediately inform your doctor.<br><br>You must not breast feed while you are treated with TAXOTERE.<br><br>If you are a man being treated with TAXOTERE you are advised must not father a child and must use an effective method of contraception during treatment and for 4 months after end of treatment with this medicine. It is recommended to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility." under sub-section Pregnancy, breast-feeding and fertility | 13/12/2023 | Sanofi Aventis Limited |
| | | | | | | |
| 10 | Trajenta | Linagliptin | Children and Adolescents | Revision of text to read "Trajenta is not recommended for children and adolescents under 18 years. It is not effective in children and adolescents between the ages of 10 and 17 years. It is not known if this medicine is safe and effective when used in children younger than 10 years" | 25/10/2023 | Boehringer Ingelheim |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 10 | Trajenta | Linagliptin | Posology and method of administration | Revision of text to read "A clinical trial did not establish efficacy in paediatric patients 10 to 17 years of age (see section 4.8, 5.1 and 5.2). Therefore, treatment of children and adolescents with linagliptin is not recommended. Linagliptin has not been studied in paediatric patients under 10 years of age." under sub section Paediatric population | 25/10/2023 | Boehringer Ingelheim |
| | | | Undesirable effects | Addition of text to read "Overall, in clinical trials in paediatric patients with type 2 diabetes mellitus aged 10 to 17 years, the safety profile of linagliptin was similar to that observed in the adult population." under sub-section Paediatric population. | | |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 11 | Trevicta | Paliperidone | Possible side effects | Deletion of text "Leakage of milk from the breasts" under the sub-section "Common side effects: may affect up to 1 in 10 people"<br><br>Deletion of text "decrease in platelets (blood cells that help you stop bleeding)"under sub-section "Uncommon side effects: may affect up to 1 in 100 people"<br><br>Deletion of text "congestion of breathing passage"under sub-section "Uncommon side effects: may affect up to 1 in 100 people"<br><br>Deletion of text "wheezing"under sub-section "Uncommon side effects: may affect up to 1 in 100 people"<br><br>Deletion of text "neck pain"under sub-section "Uncommon side effects: may affect up to 1 in 100 people"<br><br>Addition of text "abscess under the skin"under sub-section "Uncommon side effects: may affect up to 1 in 100 people"<br><br>Addition of text "flaky itchy scalp or skin"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Addition of text "decrease in platelets (blood cells that help you stop bleeding)"under sub-section "Rare side effects: may affect up to 1 in 1,000 people" | 22/11/2023 | Janssen |

| No. | Name of Drug | Active Ingredient(s) | Updated Section | Update | Date of Update | MAH |
|---|---|---|---|---|---|---|
| 12 | Trevicta | Paliperidone | Possible side effects | Addition of text "shaking of the head"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Deletion of text "abcess under the skin"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Addition of text "blood clot in the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Addition of text "congestion of breathing passages"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Addition of text "wheezing"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Addition of text "a blockage in the bowels"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Addition of text "priapism (a prolonged penile erection that may require surgical treatment)"under sub-section "Rare side effects: may affect up to 1 in 1,000 people"<br><br>Deletion of text "shaking of the head"under sub-section "Not known: frequency cannot be estimated from the available data" | 22/11/2023 | Janssen |